Informa

AsiaTIDES: Oligonucleotide & Peptide Therapeutics
-AsiaTIDES:寡核苷酸及胜肽療法-
日期:2019年2月26-28日
地點:日本,千葉縣,Hilton Tokyo Bay Hotel

本活動是亞洲地區唯一介紹有助於加速寡核苷酸及胜肽療法上市作業的研究成果與技術,並提供合作機會的活動

Choose your language
Chinese
Japanese
Korean
English

AsiaTIDES 2019的主要講者與講題

寡核苷酸

寡核苷酸療法開發的新策略與技術
Thazha Prakash, Ph.D., Director, Medicinal Chemistry, Ionis Pharmaceuticals, USA

處於第一期/前期、第二期臨床試驗的治療濕眼式老年黃斑部病變(wet AMD)的抗FGF2適體 – RBM-007
Yoshikazu Nakamura, Ph.D., President and CEO, RIBOMIC Inc., and Professor Emeritus, The University of Tokyo, Japan

新RNA療法:可用於mRNA及siRNA的運送方法
Shiro Akinaga, Ph.D., Director, Chief Scientific Officer, AccuRna Inc., Japan

題目將於日後公布
Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals

從立體化學純度到精密醫療:最佳化反股核酸療法的特性
WAVE Lifesciences, Speaker TBA


mRNA療法

mRNA療法入門
Jim Thompson, Ph.D., Head CMC Project Management, Moderna Therapeutics, USA

新mRNA免疫療法
Robert Jabulowsky, Ph.D., Deputy Head of Project Management, BioNTech AG, Germany

mRNA療法開發
Nigel Horscroft, D.Phil., Area Head, Molecular Therapy, CureVac AG, Germany 

mRNA藥物運送的最佳化
Peter Lutwyche, Ph.D., Chief Technology Officer, Genevant Sciences Corporation, Canada 

寡核苷酸及胜肽療法的法規面課題

寡核苷酸及胜肽療法的法規策略,以及中國國家食品藥品監督管理總局(CFDA)法規改革的最新情報
Dan Zhang, M.D., Co-Founder & CEO, Fountain Medical Development, China

胜肽與醫療儀器組合產品開發相關法規課題
Duu-Gong Wu, Ph.D., Senior Director, Regulatory Consulting, PPD (and Former Deputy Division Director of Division of New Drug Chemistry, CDER, FDA), USA 

寡核苷酸療法的法規策略
David T. Lin, Ph.D., Senior Consultant, Biologics Consulting, (Former Chemistry Team Leader and Former Acting Division Director, Division of New Drug Chemistry, CDER, FDA), USA

 

寡核苷酸(續)

次世代鎖核酸
Konrad Bleicher, RNA Therapeutics, Roche Pharma Preclinical Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann-La Roche Ltd., Switzerland

題目將於日後公布
Satoshi Inoue, Ph.D., Scientist, Bio-functional Molecular Chemistry Group, Ajinomoto Co., Inc., Japan

胜肽

環狀構造及二環狀結構的遺傳符號化選擇
Ratmir Derda, Ph.D., Associate Professor, Department of Chemistry, University of Alberta, Canada

液態胜肽製造工程用的永續性低公害型溶劑導入
El Djouhar Rekai, Ph.D., Head of Development & Manufacturing Process, PolyPeptide Group, Belgium

胜肽的品質特性與美國FDA標準
Ranjan Chakrabarti, Ph.D., Vice President & Head - Global Biologics Lab and Standards, United States Pharmacopeia, India

ZEOsphere DRP混合模式層析的高性價比胜肽純化
Jurgen Machielse, Business Development Director, Zeochem AG, Switzerland

胜肽合成的線性收斂方法 – 製造商觀點比較
Daniel Samson, Ph.D., Vice President API SPPS, Bachem AG, Switzerland

胜肽(續)

合成胜肽原藥的課題
Robert Hagopian, Director Business Development, PolyPeptide Group

對應早期開發階段的分析法、預備處方、處方
Christopher Rhodes, Ph.D., President and CEO, Drug Delivery Experts 

毒性學與生物學分析的策略/第一階段臨床試驗的策略
Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahest

美國胜肽藥與胜肽生物製劑間,產品開發的相似及相異之處
Duu-Gong Wu, Ph.D., Senior Director, Regulatory Consulting, PPD (and Former Deputy Division Director of Division of New Drug Chemistry, CDER, FDA), USA

請勿錯過這個能夠在ASIATIDES找尋業務發展時不可或缺之研究成果、技術、合作夥伴的機會

加速產品上市

除了可以聆聽全球正在進行第2及第3期臨床試驗的寡核苷酸、肽治療藥開發企業的案例研討和最佳範例相關演講,並將由產業領袖分享從申請到核准成功推動IND/IMPD的指南和Roadmap,以確保產品通過審核。

評估新技術和服務

透過與20多間全球領導技術開發企業的會晤,改善您的製程開發、分析、製造作業。此外也在展示會大廳安排了海報發表,將展示全球研究人員針對寡核苷酸及肽開發各階段的最新研究成果。

與新合作夥伴會面

透過午餐、晚餐、招待會等機會,能夠與300多位來自亞洲、歐洲、北美等地的寡核苷酸及肽研究領導者建立人脈。

AsiaTIDES 2019諮詢委員會

  • Hiroaki Suga, Ph.D., Professor of Chemistry, School of Science, University of Tokyo, Japan 
  • Osamu Sato, Executive Director, R&D Planning Department, Daiichi Sankyo, Japan 
  • Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals 
  • James Thompson, Ph.D., Head of CMC Project Management, Moderna Therapeutics, Inc. 
  • Hideaki Sato, President and CEO Luxna Biotech
  • Robert Hagopian, Director Business Development, PolyPeptide Laboratories, USA
  • Daisuke Takahashi, Ph.D., Senior Principal Researcher, Bio-functional Molecular Chemistry Group, Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto. Co., Inc., Japan
  • Dong-ki Lee, Ph.D., Professor, Sungkyunkwan University and CEO & Founder, OliX Pharmaceuticals, Korea 
  • Shawn Lee, Ph.D., President and CEO, CPC Scientific, USA and China 
  • Patrick Lu, Ph.D., Founder, President and CEO, Sirnaomics, Inc., USA 
  • Michael McGinley, Global Technical Manager, Phenomenex, USA
  • Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahest 
  • El Djouhar Rekai, Head of Peptide Products Operation, PolyPeptide Group, Belgium G. 
  • Susan Srivatsa, Ph.D., President, ElixinPharma, USA 
  • Dmitry Samarsky, Ph.D., Industry Expert 
  • Mimoun Ayoub, Ph.D., Director and Head of North American and Emerging Markets, CordenPharma International, Switzerland